The EPS projection of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for quarter ended 2016-09-30 is $-0.78. A week before, the EPS forecast was $-0.78 against target of $-0.78, a month earlier. This estimate stood at $-0.78 60 days earlier versus forecast of $-0.78 90 days earlier, confirming a deviation of 0%.
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) reported that 18 days ago, the positive EPS revisions were 1 and negative revisions at 2.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 1, 1, 0 and 1, respectively.
The downgrade of EPS estimates for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) in the preceding 120, 60, 30 and 90 days were 2, 2, 0 and 2, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) was $-0.78. This projection was computed after accounting 4 calls. As reported on 2016-05-05 the EPS was $-0.49. The change was $0.14, demonstrating a percentage deviation of 22.22%. The projections confirmed a standard deviation of 0.36.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) stands at $8.743 and the median estimate at $7.1. Almost 3 analysts announced their estimates.
The highest estimate is $15 while the lowest target is $4.13 showing standard deviation of 5.618%.
As many as 3 analysts released sales estimates reised in upside while 3 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 3 revised sales number projection on upside while 3 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 3 hiked sales estimations and 3 reduced sales forecast. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) stated that the change in forecast was -18.616%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...